ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Clinical Practice Article

Simple Clinical Presentation of a Complicated Disease: The Story of Two Women with MEN 1

[version 1; peer review: awaiting peer review]
PUBLISHED 16 Apr 2025
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS AWAITING PEER REVIEW

Abstract

Background

Multiple Endocrine Neoplasia Type 1 (MEN 1) is a rare hereditary disorder characterized by tumors in the parathyroid, pancreatic islet cells, and anterior pituitary. This study discusses two distinct clinical cases to illustrate the diverse manifestations, diagnostic challenges, and management strategies for MEN 1.

Methods

A case-based approach was employed to examine the clinical presentation, biochemical findings, imaging results, and therapeutic interventions in two patients with MEN 1. Relevant literature was reviewed to contextualize the findings.

Results

Case 1 involved a 47-year-old female presenting with hyperparathyroidism and a gastrinoma, managed conservatively due to comorbid chronic kidney disease. Case 2 featured a 26-year-old female with aggressive manifestations, including severe osteoporosis, hypercalcemia, and a pancreatic tail lesion, necessitating prompt surgical intervention. Both cases highlighted the utility of advanced imaging (Tc99 MIBI scans, MRI) and biochemical markers (serum calcium, iPTH, chromogranin A) in diagnosis and management. Genetic testing was emphasized as a key component of family screening and long-term surveillance.

Discussion

MEN 1 requires a multidisciplinary approach due to its multisystemic nature. Early diagnosis and tailored interventions, including parathyroidectomy and medical therapies like cinacalcet and somatostatin analogs, are critical to optimizing outcomes. The variability in clinical presentations underscores the need for personalized management plans.

Conclusion

The diverse spectrum of MEN 1 demands vigilant surveillance and a collaborative healthcare approach. Advances in diagnostics and targeted treatments continue to improve patient outcomes, but long-term management and genetic counseling remain pivotal.

Keywords

MEN 1, hyperparathyroidism, neuroendocrine tumors, genetic counseling, Tc99 MIBI scans, multidisciplinary management.

Introduction

Multiple Endocrine Neoplasia Type 1 (MEN1), also known as Wermer’s syndrome, is a rare hereditary disorder characterized by the predisposition to develop tumors in multiple endocrine organs. MEN1 is caused by mutations in the MEN1 gene located on chromosome 11, which encodes the tumor suppressor protein menin. This syndrome primarily involves the parathyroid glands, endocrine pancreas, and anterior pituitary, although other tissues and organs may also be affected. MEN1 follows an autosomal dominant pattern of inheritance, with a prevalence of approximately 2 in 100,000 individuals. The condition poses significant diagnostic and management challenges due to its multisystemic involvement and variable clinical presentation.1,2 Parathyroid tumors are the most common manifestation of MEN1, occurring in over 90% of cases. These tumors often lead to primary hyperparathyroidism, which presents early, usually in the second or third decade of life, compared to sporadic hyperparathyroidism seen later in life. In MEN1-associated hyperparathyroidism, multiple glands are typically involved, and there is a higher rate of recurrence after surgery compared to sporadic cases. This condition often results in hypercalcemia, leading to symptoms such as bone pain, fractures, nephrolithiasis, and fatigue, further complicating the patient's clinical course. Gastroenteropancreatic neuroendocrine tumors (NETs) are another hallmark of MEN1, affecting up to 70% of individuals with the syndrome. These tumors, including gastrinomas, insulinomas, and non-functioning pancreatic NETs, often exhibit an aggressive clinical course and can result in severe symptoms such as refractory peptic ulcers, diarrhea, hypoglycemia, and abdominal pain. Despite advancements in imaging and biochemical tests, these tumors are often diagnosed late, when they have already metastasized, making management more complex.

Pituitary adenomas, which occur in approximately 15-90% of MEN1 cases, add another layer of complexity to the syndrome. While many are non-functioning, some secrete prolactin or growth hormone, leading to clinical manifestations such as galactorrhea, menstrual disturbances, acromegaly, or gigantism. These adenomas are often resistant to conventional treatment and may require surgical or medical intervention.3

The variable penetrance and expression of MEN1 make its diagnosis particularly challenging. Patients may initially present with symptoms from one organ system, such as recurrent kidney stones or refractory peptic ulcer disease, leading to delayed recognition of the underlying syndrome. Early diagnosis is critical, as MEN1-related tumors often follow a more aggressive course compared to their sporadic counterparts. Genetic testing for MEN1 mutations and screening of first-degree relatives are essential components of the diagnostic approach.

Management of MEN1 requires a multidisciplinary approach, involving endocrinologists, surgeons, radiologists, and oncologists. Treatment strategies are individualized, focusing on controlling hormonal hypersecretion, addressing tumor burden, and mitigating complications. Advances in imaging modalities, such as 68Ga-DOTATATE PET/CT, and novel therapeutic agents, including somatostatin analogs and molecularly targeted therapies, have improved the diagnostic and therapeutic landscape for MEN1 patients. However, the syndrome remains a lifelong challenge due to its high recurrence rates and the need for continuous surveillance.4

This report presents two cases of MEN1, highlighting the complexities of its diagnosis and management. Through these cases, we aim to provide insights into the unique challenges posed by this rare condition and emphasize the importance of early recognition and a coordinated, multidisciplinary approach to care.

Case presentation: MEN type 1 syndrome in two patients

Multiple Endocrine Neoplasia Type 1 (MEN 1), also known as Wermer’s syndrome, is a rare hereditary condition that involves the development of tumors in endocrine glands such as the parathyroid, anterior pituitary, and pancreatic islet cells. This report discusses two distinct cases of MEN 1, detailing their clinical presentations, investigations, and management.

Case 1: A 47-Year-Old Female

Clinical Presentation A 47-year-old unmarried female with a history of chronic kidney disease (CKD) and hypothyroidism presented with a five-day history of watery diarrhea, nausea, and vomiting. The diarrhea was waxing and waning in nature, and there was no associated fever, pain abdomen, or weight loss. She had a prior history of hospital admissions for similar complaints and was managed with IV fluids, antibiotics, and probiotics, which showed minimal improvement.

On examination, she was noted to have mild pallor and clinical signs of dehydration. No lymphadenopathy or hepatosplenomegaly was observed. The physical examination of the abdomen was unremarkable.

Investigations and Findings The investigations revealed significant abnormalities, as summarized in Table 1. Key findings included elevated serum calcium and iPTH levels in both cases, imaging-confirmed parathyroid adenomas, and additional biochemical markers supporting the diagnosis of MEN 1. Upper G I Endoscopy showing multiple sessile gastric and duodenal polyps ( Figures 1), Key findings included elevated serum calcium, high iPTH levels, and imaging confirming a left lower parathyroid adenoma ( Figures 2) and MRI Brain showing pituitary adenoma (Figure 3).

Table 1. Comparative investigations in case 1 and case 2.

Investigation typeCase 1: A 47-Year-Old FemaleCase 2: A 26-Year-Old Female
Hematological Findings

  • - Hemoglobin: 9.2 g/dL; Platelets: 1.8 lakh/mm3.

  • - Hemoglobin: 10.8 g/dL; Platelets: Normal.

  • - TLC: 4,500/mm3.

  • - Mild anemia noted.

Biochemical Findings

  • - Severe hypercalcemia: 12.3 mg/dL; elevated iPTH: 2340 pg/mL.

  • - Severe hypercalcemia: 14 mg/dL; elevated iPTH: 855 pg/mL.

  • - High chromogranin A: 15,540 ng/mL; fasting gastrin: 1920 pg/mL.

  • - Elevated chromogranin A: 592 ng/mL.

Renal and Electrolyte Findings

  • - Creatinine: 4.8 mg/dL; Urea: 157 mg/dL; Sodium: 134 mEq/L.

  • - Creatinine: Normal; Sodium: Normal.

Imaging Findings

  • - Tc99 MIBI scan localized left lower parathyroid adenoma.

  • - Tc99 MIBI scan localized right upper parathyroid adenoma.

  • - Ultrasound showed CKD changes.

  • - MRI confirmed multiple osteolytic calvarial lesions and pancreatic tail lesion.

Trends in Biochemical Parameters

  • - Serum calcium reduced to 9.9 mg/dL post-treatment.

  • - Serum calcium dropped to 4 mg/dL post-surgery; stabilized at ~8 mg/dL.

  • - iPTH reduced to 1897 pg/mL.

  • - iPTH dropped to 5 pg/mL post-surgery.

7069aa6a-2ea1-4033-9ad7-acbf6ca46de4_figure1.gif

Figure 1. Upper G I Endoscopy showing multiple sessile gastric and duodenal polyps.

7069aa6a-2ea1-4033-9ad7-acbf6ca46de4_figure2.gif

Figure 2. 99mTc-MIBI scan highlighting left lower parathyroid adenoma, which was identified as the cause of hyperparathyroidism in Case 1.

7069aa6a-2ea1-4033-9ad7-acbf6ca46de4_figure3.gif

Figure 3. MRI Brain showing pituitary adenoma in Case 1.

Management: The patient was started on medical therapy due to her poor general condition and advanced CKD.

Parathyroid tablet(30 mg BD): To manage hypercalcemia and suppress parathyroid hormone (PTH) secretion.

  • • Octreotide (100 mcg SC TDS): For symptomatic control.

Surgery was deferred due to her poor general condition. After a week of medical management, significant improvements were observed, as detailed in Table 1.

Figures

  • • Figure 1: Upper G I Endoscopy showing multiple sessile gastric and duodenal polyps

  • • Figure 2: 99mTc-MIBI scan highlighting left lower parathyroid adenoma, which was identified as the cause of hyperparathyroidism in Case 1.

  • • Figure 3: MRI of pituitary gland showing adenoma

Case 2: A 26-Year-Old Female

A 26-year-old female presented with a one-month history of persistent headaches and lower limb pain. She had been evaluated at an external center, where imaging revealed multiple osteolytic lesions in the skull. Fine-needle aspiration cytology (FNAC) of one of these lesions demonstrated no evidence of malignancy. She also reported generalized weakness and unintentional weight loss over the past few weeks.

On physical examination, the patient appeared pale with diffuse tenderness over long bones. Neurological assessment was unremarkable, and no focal deficits were noted.

Investigations and Findings

The diagnostic workup revealed significant biochemical abnormalities, strongly indicative of MEN1 syndrome.

  • • Elevated Serum Calcium: 14 mg/dL (hypercalcemia).

  • • iPTH Levels: 855 pg/mL (elevated).

  • • 24-Hour Urinary Calcium Excretion: 398 mg/day (elevated).

  • • Bone Mineral Density Testing: Severe osteoporosis with a T-score of -4.4.

Imaging Findings:

  • • MRI Skull ( Figure 4): Demonstrated multiple osteolytic lesions, consistent with skeletal manifestations of MEN1.

  • • Tc99 MIBI Scan (TECHNETIUM TC 99M SESTAMIBI)TM ( Figure 5): Localized a metabolically active lesion in the right upper parathyroid gland, confirming parathyroid adenoma.

  • • MRI Abdomen ( Figure 6): Revealed a focal cystic lesion measuring 13x12 mm in the pancreatic tail, consistent with a pancreatic neuroendocrine tumor.

7069aa6a-2ea1-4033-9ad7-acbf6ca46de4_figure4.gif

Figure 4. MRI showing osteolytic lesions in the skull, providing evidence of the skeletal manifestations in Case 2.

7069aa6a-2ea1-4033-9ad7-acbf6ca46de4_figure5.gif

Figure 5. Tc99 MIBI scan demonstrating right upper parathyroid adenoma, confirming the diagnosis in Case 2.

7069aa6a-2ea1-4033-9ad7-acbf6ca46de4_figure6.gif

Figure 6. MRI abdomen revealing a pancreatic tail lesion, consistent with neuroendocrine involvement in MEN 1.

These findings underscored the multisystem involvement characteristic of MEN1, integrating features of hyperparathyroidism and neuroendocrine tumors. A detailed summary of these findings is provided in Table 1.

Management

The patient was initially stabilized for a hypercalcemic crisis with:

  • 1. Intravenous Fluids: To address dehydration and hypercalcemia.

  • 2. Thiazide Diuretics and Steroids: To assist in calcium homeostasis.

  • 3. Conservative Management of Fractures: Addressed femoral fracture without surgical intervention.

Surgical Intervention

The patient underwent a parathyroidectomy, after which:

  • • Postoperative Serum Calcium: Dropped to 4 mg/dL and stabilized at ~8 mg/dL with the following:

    • â—‹ Intravenous Calcium Gluconate: For immediate correction of hypocalcemia.

    • â—‹ Oral Calcium Supplementation: 1.5 g/day in three divided doses.

    • â—‹ Alfacalcidol (Vitamin D): To address osteoporosis and aid calcium absorption.

  • • Serum iPTH Levels: Decreased dramatically to 5 pg/mL post-surgery, reflecting the successful removal of the hyperactive parathyroid adenoma.

Diagnostic considerations and multidisciplinary approach

Diagnosing MEN 1 requires integrating clinical symptoms, biochemical findings, and imaging results to identify the involvement of multiple endocrine organs. In both cases, elevated serum calcium and iPTH levels were pivotal in diagnosing primary hyperparathyroidism, the most common manifestation of MEN 1. Imaging modalities like Tc99 MIBI scans and MRI confirmed the presence of parathyroid adenomas and associated neuroendocrine tumors.

The diagnostic process necessitated a multidisciplinary approach:

  • 1. Endocrinology: Managed hyperparathyroidism through biochemical monitoring and medical therapies, including cinacalcet and octreotide.

  • 2. Surgery: Performed parathyroidectomy and provided postoperative care to normalize calcium and PTH levels.

  • 3. Radiology: Utilized advanced imaging techniques to localize adenomas and detect skeletal and abdominal abnormalities.

  • 4. Oncology: Investigated neuroendocrine tumor markers such as chromogranin A and gastrin, guiding further treatment plans.

  • 5. Nephrology: Monitored renal function, particularly in Case 1, where CKD complicated management.

The combined expertise of these specialties ensured accurate diagnosis, effective treatment, and comprehensive care, highlighting the importance of collaborative management in MEN 1 cases.

Discussion

Multiple Endocrine Neoplasia Type 1 (MEN 1) is a rare autosomal dominant hereditary disorder characterized by tumors in multiple endocrine organs. The disorder stems from mutations in the MEN1 gene, which encodes the tumor suppressor protein menin. These mutations disrupt cellular growth control mechanisms, leading to the development of endocrine and non-endocrine tumors. This discussion explores the clinical complexities, diagnostic considerations, and therapeutic strategies relevant to MEN 1, informed by the two cases presented.5

Pathophysiology

The MEN1 gene mutation results in the loss of menin function, facilitating unchecked proliferation in endocrine tissues. MEN 1 primarily affects the parathyroid glands, pancreas, and anterior pituitary, though other tissues may also be involved. Hyperparathyroidism is the most common manifestation, present in over 90% of cases, and is often the earliest clinical feature. Tumors in the pancreas and gastrointestinal tract, such as gastrinomas and insulinomas, contribute significantly to morbidity. Pituitary adenomas, observed in about 30-40% of cases, frequently cause hormonal imbalances but may also be asymptomatic.5,6

In Case 1, hyperparathyroidism and a gastrointestinal neuroendocrine tumor (gastrinoma) were evident, consistent with MEN 1’s hallmark presentations. In Case 2, the combination of skeletal involvement, pancreatic tail lesion, and hyperparathyroidism underscored the syndrome's multisystemic nature.

Diagnostic challenges

The diagnosis of MEN 1 often requires integrating clinical, biochemical, and imaging findings. Symptoms may vary widely depending on the organs involved, and patients may initially present with vague or nonspecific complaints.

Biochemical Markers

Elevated calcium and intact parathyroid hormone (iPTH) levels are critical in diagnosing primary hyperparathyroidism. Additional markers, such as chromogranin A and gastrin, aid in identifying neuroendocrine tumors. In both cases, these markers provided pivotal diagnostic insights. For instance, the markedly elevated chromogranin A and fasting serum gastrin in Case 1 confirmed the presence of a gastrinoma.

Imaging Modalities

Advanced imaging techniques play a central role in localizing tumors and guiding management. Tc99 MIBI scans are highly effective for identifying parathyroid adenomas, as demonstrated in both cases. MRI and CT imaging further delineate the extent of organ involvement and assess for metastatic disease. In Case 2, MRI revealed osteolytic skull lesions and a pancreatic tail neoplasm, underscoring the systemic involvement of MEN 1.7

Genetic Testing

While genetic confirmation of MEN 1 is definitive, it is often not immediately necessary for clinical diagnosis. Genetic testing, however, has significant implications for family screening and early detection in asymptomatic carriers. Both cases could benefit from genetic counseling to address familial risk.

Multisystem involvement and management

The multisystem nature of MEN 1 requires a comprehensive and multidisciplinary approach to management, involving endocrinologists, surgeons, radiologists, and oncologists. Each manifestation demands targeted therapeutic strategies:

Hyperparathyroidism

Primary hyperparathyroidism is the most common and earliest manifestation of MEN 1. Parathyroidectomy is the treatment of choice, particularly when symptomatic hypercalcemia or significant bone involvement is present. Case 2 exemplifies the success of this approach, with biochemical normalization post-surgery. Medical therapy with cinacalcet can be valuable in patients unfit for surgery, as in Case 1.

Neuroendocrine Tumors

Neuroendocrine tumors (NETs) in MEN 1 often secrete bioactive peptides, leading to distinct clinical syndromes. Gastrinomas, as seen in Case 1, can result in severe peptic ulcer disease. Management includes proton pump inhibitors, somatostatin analogs like octreotide, and, where feasible, surgical resection. Pancreatic NETs, such as the lesion identified in Case 2, may require surgery or targeted therapies, depending on the tumor’s functional status and metastatic potential.

Pituitary Involvement

Pituitary adenomas in MEN 1 may require medical management with hormone suppression therapies or surgical intervention in cases of significant mass effect or hormonal hypersecretion. Although not prominently featured in these cases, regular screening is essential given the high prevalence of pituitary tumors in MEN 1.

Case-specific insights

Case 1 highlights the challenges of managing MEN 1 in the presence of chronic comorbidities like CKD, which complicate surgical and medical interventions. Conservative management with cinacalcet and octreotide successfully stabilized the patient’s biochemical parameters, delaying the need for surgery. This underscores the importance of individualized treatment strategies.

In contrast, Case 2 demonstrates the more aggressive presentation of MEN 1 in a younger patient. The presence of severe osteoporosis, hypercalcemic crisis, and pancreatic involvement necessitated prompt surgical intervention. The significant improvement in biochemical parameters post-parathyroidectomy illustrates the efficacy of timely surgical management.

Long-term management and surveillance

MEN 1 is a lifelong condition requiring regular surveillance to detect new or recurrent tumors. Annual monitoring of serum calcium, PTH, chromogranin A, and imaging studies is recommended. Early detection of asymptomatic tumors can significantly improve outcomes. Genetic counseling and testing are crucial for first-degree relatives, as early identification in asymptomatic carriers enables proactive monitoring and intervention.8

Key observations and trends in MEN1 studies (2010–2025)

Multiorgan Involvement: MEN1 patients frequently develop tumors in multiple endocrine glands, primarily affecting the parathyroid, pancreas, and pituitary glands. Some cases also present with skeletal involvement (osteolytic lesions) or mediastinal masses, underscoring the need for a comprehensive diagnostic approach shown in Table 2.

Table 2. Comprehensive Comparative Analysis of MEN1 Studies.9,10

Study & YearAuthorsStudy TypePatient DetailsPrimary Clinical PresentationDiagnostic ApproachImaging Modalities UsedGenetic TestingTreatment StrategyFollow-up Recommendations
Current Study (2025) Anamitra Hait, Maheshkumar Baladaniya, Joydeep Ghosh, Arbind Kumar ChoudharyCase Study (2 cases)Case 1:47-year-old female Case 2:26-year-old femaleCase 1:Hyperparathyroidism, gastrinoma, CKD Case 2:Osteoporosis, hypercalcemia, pancreatic lesionSerum calcium, iPTH, Chromogranin A, GastrinTc99 MIBI scan, MRI brain & abdomen, upper GI endoscopyNot performed but recommended for family screeningCase 1: Medical therapy (Cinacalcet, Octreotide) Case 2:Surgery (Parathyroidectomy) + calcium & vitamin D supplementationRegular biochemical monitoring (Ca, iPTH, Chromogranin A), imaging surveillance, genetic counseling
Keller et al. (2018) Hilary R. Keller, Jessica L. Record, Neil U. LallCase ReportMale in early 30sEpigastric pain, nausea, vomiting, diarrhea; history of hyperparathyroidism and prolactinoma resectionSerum calcium, iPTH, Chromogranin AContrast-enhanced CT, MRI abdomen, Tc99 MIBI scanNot performed but recommendedSurgical resection (parathyroid adenoma, pancreatic tumor), medical managementPost-surgical biochemical monitoring, imaging follow-up, genetic counseling
Kamilaris & Stratakis (2019) Crystal D. C. Kamilaris, Constantine A. StratakisReview ArticleNot applicableOverview of MEN1 clinical features and managementLiterature reviewNot applicableDiscussion on MEN1 genetic mutationsRecommendations for surgical and medical therapiesEmphasis on early genetic testing and multidisciplinary follow-up
Kouvaraki et al. (2006) Maria A. Kouvaraki, Jeffrey E. Lee, Douglas B. Evans, et al.Retrospective Study108 patients (mean age 41 years)Various MEN1 manifestationsComprehensive genetic analysisNot specifiedMEN1 mutations identified in 89% of patientsSurgical interventions based on tumor type and sizeRegular surveillance and genetic counseling

Diagnostic Markers and Biochemical Evaluation: Elevated serum calcium and intact parathyroid hormone (iPTH) levels are consistent indicators of primary hyperparathyroidism, the most common MEN1 manifestation. For neuroendocrine tumors (NETs), Chromogranin A and Gastrin serve as valuable biomarkers, while fasting insulin and C-peptide levels are crucial for diagnosing insulinomas.

Role of Imaging in MEN1 Diagnosis: A combination of imaging techniques is essential for tumor localization and staging. Tc99 MIBI scans are effective for identifying parathyroid adenomas, whereas MRI and CT scans are preferred for detecting pancreatic and pituitary tumors. PET scans are utilized selectively, particularly in cases of suspected metastatic disease.

Genetic Testing and Family Screening: Given the hereditary nature of MEN1, genetic testing is crucial for confirming diagnoses and screening at-risk family members. Identifying asymptomatic carriers facilitates early detection and preventive care.

Treatment Strategies: Surgery vs. Medical Management: Surgical interventions, such as parathyroidectomy and tumor resection, are standard treatments for MEN1-related tumors. In cases where surgery is not feasible, medical therapies like Cinacalcet and Somatostatin analogs are effective for hormonal control and symptom management.

Follow-up and Long-Term Surveillance: Due to the lifelong risk of tumor recurrence, structured long-term follow-up is essential. Annual biochemical screeningsand routine imaging are recommended to detect early tumor recurrence or new growths. Additionally, genetic counseling is vital for at-risk family members to ensure proactive disease management.

Conclusion

The two cases illustrate the diverse clinical spectrum of MEN 1, ranging from mild to severe systemic involvement. The complexities of diagnosis and management necessitate a multidisciplinary approach tailored to individual patient needs. Advances in biochemical and imaging diagnostics, coupled with targeted medical and surgical therapies, continue to enhance outcomes for patients with this challenging syndrome. Long-term surveillance and genetic counseling remain pivotal in managing MEN 1 and preventing complications in affected families.

Consent to publish

Written informed consent was obtained from the patient for the publication of this case report, including accompanying images and data.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 16 Apr 2025
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Hait A, Baladaniya M, Ghosh J and Chaudhary AK. Simple Clinical Presentation of a Complicated Disease: The Story of Two Women with MEN 1 [version 1; peer review: awaiting peer review]. F1000Research 2025, 14:443 (https://doi.org/10.12688/f1000research.161366.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status:
AWAITING PEER REVIEW
AWAITING PEER REVIEW
?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 16 Apr 2025
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.